BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Rome
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20230312T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20231105T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20240310T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20241103T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/La_Paz
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0400
TZNAME:-04
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241111
DTEND;VALUE=DATE:20241114
DTSTAMP:20240505T173640Z
CREATED:20240505T173640Z
LAST-MODIFIED:20240505T173640Z
UID:61165-1731283200-1731542399@globalbiodefense.com
SUMMARY:Pandemic Preparedness: Achievements\, Current Challenges\, and New Frontiers
DESCRIPTION:The Pandemic Preparedness: Achievements\, Current Challenges\, and New Frontiers conference will be held 11-13 November 2024 in Trieste\, Italy. \nJoin world-renowned scientists discussing the known and emerging viruses representing a potential epidemic risk. \nThe event will focus on prevention\, surveillance\, detection\, drug discovery\, treatment\, and cooperation\, to tackle challenges and implementing response strategies related to the threat posed by potential pandemic outbreaks. \nHighlighted topics include: \n\nEmerging and re-emerging viruses with pandemic potential\nRisk of viral zoonoses and its mitigation\nDiagnostics\, surveillance and capacity building in resources limited settings\nImmunization and preventive approaches\nDrug discovery: stocking the shelves for the next pandemic\nBiosafety and Biosecurity when dealing with viral infections\nMultidisciplinary approaches\, infrastructure\, and cooperation\nFuture challenges in pandemic preparedness\n\nThe conference is organized by Area Science Park\, in conjunction with the International Centre for Genetic Engineering and Biotechnology – ICGEB\, in the framework of PRP@CERIC project. \nPlease visit the Pandemic Preparedness: Achievements\, Current Challenges\, and New Frontiers website for more information.
URL:https://globalbiodefense.com/event/pandemic-preparedness-achievements-current-challenges-and-new-frontiers/
LOCATION:Savoia Excelsior Palace\, Riva del Mandracchio\, Trieste\, 34124\, Italy
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241113
DTEND;VALUE=DATE:20241118
DTSTAMP:20240218T222149Z
CREATED:20240218T221646Z
LAST-MODIFIED:20240218T222149Z
UID:60041-1731456000-1731887999@globalbiodefense.com
SUMMARY:ASTMH 2024 - American Society of Tropical Medicine & Hygiene
DESCRIPTION:The American Society of Tropical Medicine & Hygiene will host the ASTMH 2024 Annual Meeting from 13-17 November 2024 in New Orleans\, Louisiana. \nThe meeting is designed for researchers\, professors\, government and public health officials\, military personnel\, travel clinic physicians\, practicing physicians in tropical medicine\, students\, and all healthcare providers working in the fields of tropical medicine\, hygiene\, and global health. \nLast year’s ASTMH Annual Meeting included over 3\,000 total presentations\, with about half being microbe-focused\, 13% vector-focused\, 15% clinically-focused\, 13% globally-focused and 6% intervention-focused. \nLearn more and register for the ASTMH 2024 Annual Meeting.
URL:https://globalbiodefense.com/event/astmh-2024-american-society-of-tropical-medicine-hygiene/
LOCATION:Ernest N. Morial New Orleans Convention Center\, 900 Convention Center Blvd\, New Orleans\, LA\, 70130\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241114T093000
DTEND;TZID=America/New_York:20241114T170000
DTSTAMP:20241107T191142Z
CREATED:20241107T191142Z
LAST-MODIFIED:20241107T191142Z
UID:61954-1731576600-1731603600@globalbiodefense.com
SUMMARY:Integration Site Analysis During Long Term Follow-Up for Gene Therapies with Integrating Viral Vectors
DESCRIPTION:The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) is hosting a virtual scientific public workshop on the clinical use of integration site analysis (ISA) during long term follow-up following administration of gene therapies with integrating viral vectors. \nIn this workshop\, FDA will convene a panel of external experts to discuss the risk of insertional mutagenesis and best practices for ISA method design\, data analysis\, and clinical interpretation. The workshop participants will include research scientists with experience in vector design and ISA\, as well as clinician-scientists with expertise in clinical interpretation of ISA data. \nFocus for this Workshop\nAs of 2024\, twelve approved and hundreds of investigational cell-based gene therapies use integrating viral vectors. While stable integration may have considerable therapeutic benefits\, integration into genomic DNA can alter host gene expression and may contribute to secondary malignancies via insertional mutagenesis. Additionally\, the choice of vector (e.g.\, lentivirus versus gammaretrovirus) and cell substrate (e.g.\, T cells versus CD34+ cells) may also contribute to this risk. \nISA is the established approach to identify vector insertion sites. However\, ISA method design and data interpretation are highly complex and product-specific. Moreover\, ISA methods may be costly and challenging to perform. There is a critical need to understand the best practices for product design and ISA method design\, execution\, and interpretation to facilitate efficient evaluation of complex gene therapy products and protect the public from potential serious adverse events. \nThis workshop will include discussions on the following topics: \n\nEffects of Cell Substrate and Vector Design on the Risk of Vector Insertion-Related Adverse Events\nISA Methodology\, Assay Design\, and Analytical Capabilities\nISA Analysis\, Quality Control\, and Data Reporting\nClinical Follow-Up for Integrating Viral Vectors\nUsing ISA to Inform Clinical Decisions\n\nFor current guidance on the role of ISA in clinical follow-up\, please refer to section V.F “Special Considerations Regarding Integrating Vectors” of the FDA Guidance for Industry “Long Term Follow-Up After Administration of Human Gene Therapy Products” dated January 2020 (https://www.fda.gov/media/113768/download). \n Registration is required.
URL:https://globalbiodefense.com/event/integration-site-analysis-during-long-term-follow-up-for-gene-therapies-with-integrating-viral-vectors/
CATEGORIES:Conference,Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241118
DTEND;VALUE=DATE:20241120
DTSTAMP:20240623T192942Z
CREATED:20240125T194316Z
LAST-MODIFIED:20240623T192942Z
UID:59697-1731888000-1732060799@globalbiodefense.com
SUMMARY:G20 Summit Rio 2024
DESCRIPTION:The G20 Leaders’ Summit is scheduled for 18-19 November 2024\, in Rio de Janeiro\, with the presence of the leaders of the 19 member countries\, plus the African Union and the European Union. \nThe G20 brings together the countries with the largest economies in the world. The member states meet annually to discuss economic\, political and social initiatives. The group defines itself as the main forum for international economic cooperation. \nThe G20 countries account for half the world’s land mass\, two-thirds of the world’s total population\, and a staggering 85% or more of global GDP. These imply both a large magnitude of health burden on the one hand and a depth of experience and strong base of resources on the other. The G20 Health Working Group was established under the German Presidency in 2017 to develop a shared international agenda on issues such as strengthening health-care systems\, reducing malnutrition\, health-crisis management\, and scaling up the fight against pandemics; these are India’s domestic priorities too. \nIn addition to the summit\, more than 100 meetings of working groups and task forces will comprise the G20 event\, both face-to-face and virtual\, at technical and ministerial level\, in the host cities of Brasil’s five regions. The highlight will be the Summit in Rio de Janeiro. \nThe participating countries are Argentina\, Australia\, Brasil\, Canada\, China\, France\, Germany\, India\, Indonesia\, Italy\, Japan\, Mexico\, Republic of Korea\, Republic of South Africa\, Russia\, Saudi Arabia\, Turkey\, United Kingdom and the United States of America\, African Union and European Union. In addition\, invited guest countries and international organizations participate in the G20. Media reports indicate the Presidents of Russia\, China and Mexico will not be in attendance. State leaders from the other member states will likely attend. \nThe G20 troika system was officially adopted at the Cannes Summit (France) in 2011 as the framework for steering the G20 process. The “troika” consists of the current\, previous\, and next G20 presidencies and the three members cooperate with one another in preparing for the G20 Summit. During Brasil’s presidency\, we will work closely together with India (2023 presidency) and South Africa (2025 presidency). \nPlease visit the G20 Brasil 2024 website for more information on the full summit agenda.
URL:https://globalbiodefense.com/event/g20-summit-rio-2024/
LOCATION:Museu de Arte Moderna do Río de Janeiro\, Av. Infante Dom Henrique\, 85\, Rio de Janeiro\, Brazil
END:VEVENT
END:VCALENDAR